Northeastern University
Bouvé College *of* Health Sciences
School *of* Pharmacy

Thursday, November 8, 2018
7:30 AM – 5:30 PM

Crowne Plaza Hotel — Pittsfield–Berkshires
1 West Street
Pittsfield, MA 01201

413-499-2000

COMPOUNDING: Implementing Best Practices for Sterile and Non-Sterile Compounding 2018

Target Audience

This continuing pharmacy education activity is designed to meet the re-licensure requirements of all Registered Pharmacists. This program is NOT accredited for Pharmacy Technicians.

Schedule of Educational Activities:

Part I Compounding: Implementing Best Practices for Sterile Compounding – 2018

7:30 – 8:00 am	Registration and Continental Breakfast
8:00 – 9:00 am	*USP <800> Handling Hazardous Drugs in Healthcare Settings: Considerations for Sterile Products and Compounding*
9:00 – 9:30 am	*"Risky Business" – Assessment of Risk on Hazardous Drugs in Sterile Compounding*
9:30 – 10:15 am	*FDA 2018 – Compounding Policy Priorities Plan*
10:15 – 10:30 am	Break
10:30– 11:15 am	*"The Real News" Q&A with expert panel on assessing, handling and remediation of hazardous sterile preparations in the healthcare setting.*
11:00 – 11:45 am	*Biological Safety Cabinets for Pharmacy*
11:45 – 12:45 pm	Lunch
12:45 – 1:30 pm	*Flash Forward: A Comparative Review of Current vs. Proposed USP <797> Standards*
1:30 – 2:00 pm	*Sterile Compounding Regulatory Update: 2018*

Part II Compounding: Implementing Best Practices for Non-Sterile Compounding – 2018

2:15 – 2:30 pm	*Complex Non-Sterile Compounding Regulatory Update: 2018*
2:30 – 4:15 pm	*USP <800> Handling Hazardous Drugs in Healthcare Settings: Considerations for Non-Sterile Products and Compounding*
	"Risky Business" – Assessment of Risk on Hazardous Drugs in Non-Sterile Compounding
	How USP <800> Applies to Veterinary Compounding
	"Fact or Fiction" Q&A with expert panel on interpreting USP 797, state regulations and handling as well as assessment of hazardous Non-Sterile compounding.
4:15 – 4:30 pm	Break
4:30 – 5:30 pm	*Critical Pharmaceutical Calculations for Non-Sterile Compounding*

Registration Information

Go to **http://www.rxce.neu.edu**. Click on Live programs; Register/Log in or create an account; at Participant Menu choose: Available Live Programs;

Choose June 21, 2018 **Compounding: Implementing Best Practices of 2018**

Registration Fee Options

$150.00	**Compounding: Implementing Best Practices for Sterile Compounding (5 contact hours)**
$100.00	**Compounding: Implementing Best Practices for Non-Sterile Compounding (3 contact hours)**
$225.00	**Compounding: Implementing Best Practices for Sterile and Non-Sterile Compounding (8 contact hours)**

No walk-ins, refunds or telephone reservations.

Faculty

Patrick Carpenter, BSP, MS, PharmD
MenMD, Director of Clinical Affairs

Michelle A. Chan, RPh
Quality Assurance Pharmacist, Massachusetts Board of Registration in Pharmacy

Michael Cotugno, BSPharm, RPh
Director of Pharmacy Patient Care Services at Brigham and Women's Hospital

Paul Fanikos, PharmD, RPh
Director of Clinical Education Programs at Alosa Health

Timothy Fensky, RPh, FACA
Compounding Pharmacist, Sullivan's Pharmacy

Janelle Ogle, CPT, Director of Quality Assurance
Johnson Compounding and Wellness

Omar Allibhai, PharmD, RPh, FACA, FIACP
Compounding Pharmacy Fellow, Johnson Compounding and Wellness

Brian Marquis, RPh
PharmaCerts, LLC

Kathleen Taylor, RPh, FACVP
Animal Pharm, LLC

Anita Young, EdD, RPh

Learning Objectives

Compounding: Implementing Best Practices for Sterile Compounding – 2018

At the end of this program, participants should be able to:

- Describe the scope of USP <800> in sterile compounding
- Identify hazardous drugs under USP <800> and potential for risk assessments
- Describe the use of personal protective equipment and staff training requirements
- Describe the requirements for receiving, storage, transportation and administration of hazardous drugs
- Give examples of exposure to Hazardous Drugs for Institutional/Infusion Facilities
- Illustrate a Risk Assessment protocol based on the examples of exposure
- Summarize the FDAs overall 2018 Compounding Policy Plan
- Explain how your practice is affected by the FDAs Plan
- Recall overall contents of the FDA Plan for further evaluation
- Summarize best practice principles of assessing, handling and remediation of hazardous sterile preparations into pharmacy planning.
- Differentiate between types of Biological Safety Cabinets
- Select the correct Biological Safety Cabinets for your application
- Demonstrate proper usage of Biological Safety Cabinets
- Recall Current USP <797> Standards
- Summarize Proposed USP <797> Standards
- Illustrate Current vs. Proposed USP <797> standards
- Outline the process and status of the new sterile compounding regulation 247 CMR 17.
- Summarize the Board's advisories related to sterile compounding

ACPE UAN 0027-0000-18-060-L03-P (knowledge based) 5 contact hours

Compounding: Implementing Best Practices for Non-Sterile Compounding – 2018

At the end of this program, participants should be able to:

- Differentiate between the levels of non-sterile compounding
- Describe the scope of USO <800> in non-sterile compounding
- Identify hazardous drugs under USP <80> and potential risk assessments
- Describe the requirements for receiving, storage, transportation and administration of hazardous drugs
- Give examples of exposure to hazardous drugs for institutional/Infusion facilities
- Illustrate a risk assessment protocol based on the examples of exposure
- Discuss with pet owners the ramifications of living with animals that are undergoing treatment with hazardous medications
- Integrate key learnings of compounding and regulatory standards into existing pharmacy practice
- Calculate the quantity of active pharmaceutical ingredient needed in a non-sterile compound using aliquots
- Show an aggregate assay correction based on the active pharmaceutical ingredient's certificate of analysis
- Describe salt form corrections needed for a non-sterile compound
- Outline the process and status of the new non- sterile compounding regulation 247 CMR 18.
- Summarize the Board's advisories related to non-sterile compounding

ACPE UAN 0027-0000-17-061-L03-P (knowledge based) 3 contact hours

Requirements for Credit

- Program attendees can earn Continuing Pharmacy Education credits for this program by electronically logging onto the website: **http://www.rxce.neu.edu**, inserting the activity specific code number and successfully completing the activity learning assessment/evaluation form. Participant names will be checked against program attendance sheets for verification of attendance.
- Participants have 60 days to complete evaluations. After 60 days from June 21, 2018, no credit will be available for this program.
- Credits will be electronically transferred to the CPE Monitor System. No Statements of Credit will be issued by Northeastern University School of Pharmacy.
- Program participants can earn up to 8 contact hours of continuing education credits in pharmacy law.

Evaluation

All participants will have the opportunity to review the educational sessions and speakers and to identify future educational needs.

Statement of Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Standards for Continuing Pharmacy Education 2009, Northeastern University School of Pharmacy requires that faculty members disclose any relationship (e.g., shareholder, recipient of research grant, consultant or member of an advisory committee) that the faculty may have with commercial companies whose products or services may be mentioned in their presentations. Such disclosure will be made available on the day of the program.

Accreditation Statement

Northeastern University Bouvé College of Health Sciences School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Northeastern University

Bouvé College of Health Sciences
School of Pharmacy

360 Huntington Avenue, R218 TF
Boston, MA 02115

617.373.3069

schoolofpharmacy@northeastern.edu